

# BUY


Price: Eu3.54 - Target: Eu4.70


## Good 2022 Results, FY23 Guidance Confirmed

## Andrea Randone +39-02-77115.364

andrea.randone@intermonte.it

Stock Rating			
Rating:			Unchanged
Target Price (Eu):			Unchanged
	2023E	2024E	2025E
Chg in Adj EPS	1.5%	1.0%	





CIVITANAVI STSTEMS
 CIVITANAVI SYSTEMS Rel. to FTSE All Shares (Reb.)

## Stock Data

SLUCK Data				
Reuters code:			CNS.MI	
Bloomberg code	:		CNS IM	
Performance	1M	3M	12M	
Absolute	2.3%	-21.2%	-10.9%	
Relative	10.3%	-28.6%	-15.6%	
12M (H/L)			4.71/3.37	
3M Average Vol	ume (th):		14.48	
Shareholder Dat	ta			
No. of Ord shares (mn):			31	
Total no. of shares (mn):			31	
Mkt Cap Ord (Eu mn):			109	
Total Mkt Cap (Eu mn):			109	
Mkt Float - Ord (Eu mn):			30	
Mkt Float (in %):			27.4%	
Main Shareholder:				
Civitanavi Systems Ltd 72.69			72.6%	
Balance Sheet D	ata			
Book Value (Eu mn):			46	
BVPS (Eu):			1.49	
P/BV:			2.4	
Net Financial Position (Eu mn):			21	
Enterprise Value (Eu mn):			88	

- FY22 results better than expected. Civitanavi's FY22 operating revenues came in at Eu34.1mn, up 36.5% YoY and 8.4% above our Eu32mn FY22 estimate, which was aligned with management guidance (we note that on 28 October 2022 management revised guidance for 2022 revenues from Eu35mn to Eu32mn due to a lower expected contribution from the industrial business resulting from import/export problems with an Australian client). Despite the slowdown in the Industrial division (-30.6% YoY to Eu6.0mn), revenue performance was supported by a greater contribution from the Aerospace and Defence division (+71.1% YoY to Eu26.3mn) thanks to certain projects, initially planned for 2023, being brought forward to 2022 by client request. Adj. EBITDA was Eu9.9mn, up 24.5% YoY, with c.300bp of margin dilution attributable to the rise in energy costs, inflation, and prolonged shortages of electronic components. Below EBITDA, D&A, financial charges, and tax rate were lower than expected, bringing net profit to Eu7.0mn vs. the Eu4.9mn forecast. Net cash as at YE22 was Eu24.5mn compared to net debt of Eu2.9mn as at YE21, mainly thanks to the IPO proceeds (Eu22mn) and FCF of Eu6.1mn (including a Eu2.5mn NWC reduction and CapEx of Eu7mn). The board has proposed payment of a Eu4mn dividend (Eu0.13 per share) in May 2023. In FY22, order intake reached Eu41.0mn, an increase of 38% on FY21 (book to bill at 1.2x). As at YE22, the hard backlog was Eu24.3mn, +31% YoY.
- 2023 guidance confirmed. From the start of 2023 to 16 March, CNS picked up orders worth Eu16.7mn. For FY23 management confirmed guidance released in December 2022 for Eu42-Eu46mn of revenues, with an adj. EBITDA margin of 29%, in line with FY22. Unfortunately, the supply chain is showing no sign of improvements in terms of pricing and the lead-in time to source key components. The dividend distribution was proposed in light of healthy FCF generation; in the coming year CNS aims to continue to distribute part of its FCF to shareholders. Looking ahead to 2024, despite the current tough scenario (semiconductor shortages) the company remains confident of achieving strong, sustainable growth. CNS has received the green light from Canadian authorities to finalise the acquisition of a minority stake in PV Labs; closing should be announced soon.
- Updated estimates. Our 2023 revenue and EBITDA forecasts were consistent with management guidance, confirmed in the FY22 results presentation. We are leaving our estimates unchanged for the time being, even though we consider the indication on newly-acquired orders to be encouraging. In terms of reported results, our 2023 estimates now factor in the Eu4.4mn figurative costs associated with the stock compensation scheme promoted by the parent company Civitanavi Systems Ltd (this non-cash item has been restated at EPS level). The company did not set a dividend policy, in our forecast we have modelled a lower payout in the coming years.
- BUY confirmed; target Eu4.7. FY22 results were better than expected. We particularly welcome the update on new orders in the first 10 weeks of 2023 and confirmation of guidance. We remain positive on the stock as we consider Civitanavi to be well placed to capture growth, especially in the global defence market, driven by rising military spending and growing demand for ITAR-free procurement. Additional opportunities might arise during the year, including potentially through M&A.

Key Figures & Ratios	2021A	2022A	2023E	2024E	2025E
Sales (Eu mn)	24	34	43	55	69
EBITDA Adj (Eu mn)	8	10	12	16	21
Net Profit Adj (Eu mn)	4	8	7	10	13
EPS New Adj (Eu)	0.127	0.247	0.242	0.310	0.429
EPS Old Adj (Eu)	0.159	0.176	0.239	0.307	
DPS (Eu)	0.000	0.130	0.100	0.110	0.120
EV/EBITDA Adj		10.4	7.1	5.5	4.3
EV/EBIT Adj		11.7	8.5	6.8	5.3
P/E Adj	28.0	14.4	14.6	11.4	8.3
Div. Yield	0.0%	3.7%	2.8%	3.1%	3.4%
Net Debt/EBITDA Adj	0.4	-2.5	-1.7	-1.2	-1.0

The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein, and any of its parts, is strictly prohibited. None of the contents of this document may be shared with third parties without Company authorization. Please see important disclaimer on the last page of this report



#### DISCLAIMER (for more details go to DISCLAIMER)

IMPORTANT DISCLOSURES The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein and of any its parts is strictly prohibited. None of the contents of this document may be shared with third parties without authorisation from Intermonte.

This report is directed exclusively at market professional and other institutional investors (Institutions) and is not for distribution to person other than "Institution" ("Non-Institution"), who should not rely on this material. Moreover, any The information and data in this report have been obtained from sources which we believe to be reliable, although the accuracy of these cannot be guaranteed by Intermonte. In the event that there be any doubt as to their reliability, this will be clearly indicated. The main purpose of the report is to offer up-to-date and accurate information in accordance with regulations in force covering "recommendations" and is not intended nor should it be construed as a the information and data in this report have been obtained from sources which we believe to be reliable, although the accuracy of these cannot be guaranteed by Intermonte. In the event that there be any doubt as to their reliability, this will be clearly indicated. The main purpose of the report is to offer up-to-date and accurate information in accordance with regulations in force covering "recommendations" and is not intended nor should it be construed as a

solicitation to buy or sell securities.

This disclamers is constantly updated on Intermonte's website <u>www.intermonte.it</u> under LEGAL INFORMATION. Valuations and recommendations can be found in the text of the most recent research and/or reports on the companies in

question. For a list of all recommendations made by Intermonte on any financial instrument or issuer in the last twelve months consult the <u>PERFORMANCE</u> web page. Intermonte distributes research and engages in other approved activities with respect to Major U.S. Institutional Investors ("Majors") and other Qualified Institutional Buyers ("QIBs"), in the United States, via Brasil Plural Securities LLC under SEC 153-6 guidelines. Intermonte is not registered as a broker dealer in the United States under the Exchange Act of 1934, as amended (the "Exchange Act"), and is not a member of the Securities Investor Protection Corporation ("SIPC"). Brasil Plural Securities LLC is registered as a broker-dealer under the Exchange Act and is a member of SIPC.

#### ANALYST CERTIFICATION

tioned in this report the respective research analyst hereby certifies that all of the views expressed in this research report accurately reflect the analyst's personal views about any or all of the subject issuer (s) or For each company mentioned in this report the respective research analyst hereby certifies that all of the views expressed in this research report accurately reflect the analysts personal views about any or all of the subject issuer (s) or securities. The analyst (s) responsible for preparing this research report receive(s) compensation was, is or will be directly or indirectly related to the specific recommendation or view in this report. The analyst (s) responsible for preparing this research report receive(s) compensation that is based upon various factors, including intermonte's total profits, a portion of which is generated by Intermonte's corporate finance activities, although this is minimal in comparison to that generated by brokerage activities. Intermonte's internal procedures and codes of conduct are almed to ensure the impartiality of its financial analysts. The exchange of information between the Corporate Finance sector and the Research Department is prohibited, as is the exchange of information between the latter and the proprietary equity desk in order to prevent conflicts of interest when recommendations are made.

The analyst responsible for the report is not a) a resident of US; b) an associated person of a U.S. broker-dealer; c) supervised by a supervisory principal of a U.S. broker-dealer. This Research Report is distributed in the U.S. through Brasil Plural Securities LLC, 545 Madison Avenue, New York 10022.

#### GUIDE TO FUNDAMENTAL RESEARCH

The main methods used to evaluate financial instruments and set a target price for 12 months after the investment recommendation are as follows:
Discounted cash flow (DCF) model or similar methods such as a dividend discount model (DDM)

Comparison with market peers, using the most appropriate methods for the individual company analysed; among the main ratios used for industrial sectors are price/ earnings (P/E), EV/EBITDA, EV/EBIT, price/sales,

Return on capital and multiples of adjusted net book value are the main methods used for banking sector stocks, while for insurance sector stocks return on allocated capital and multiples on net book value and embedded portfolio . value are used For the utilities sector comparisons are made between expected returns and the return on the regulatory asset base (RAB) -

Some of the parameters used in evaluations, such as the risk-free rate and risk premium, are the same for all companies covered, and are updated to reflect market conditions. Currently a risk-free rate of 4.0% and a risk premium of 5.5% are being used.

#### Frequency of research: quarterly

Reports on all commanies listed on the S&PMIB40 Index, most of those on the MIDEX Index and the main small caps (regular coverage) are published at least once per quarter to comment on results and important newsflow. A draft copy of each report may be sent to the subject company for its information (without target price and/or recommendations), but unless expressly stated in the text of the report, no changes are made before it is published Explanation of our ratings system:

BUY: stock expected to outperform the market by over 25% over a 12 month period;

OUTPERFORM: stock expected to outperform the market by between 10% and 25% over a 12 month period;

NUTRAL: stock performance expected a between +10% and -10% compared to the market over a 12 month period; UNDERPERFORM: stock expected to underperform the market by between -10% and -25% over a 12 month period; SEL: stock expected to underperform the market by over 25% over a 12 month period. Prices: The prices reported in the research refer to the price at the close of the previous day of trading

## CURRENT INVESTMENT RESEARCH RATING DISTRIBUTIONS

Intermonte SIM is authorised by CONSOB to provide investment services and is listed at n° 246 in the register of brokerage firms As at 31 December 2022 Intermonte's Research Department covered 121 companies. Intermonte's distribution of stock ratings is tings is as follows

BUY:	20.66 %
OUTPERFORM:	48.76 %
NEUTRAL:	28.10 %
UNDERPERFORM	02.48 %
SELL:	00.00 %

The distribution of stock ratings for companies which have received corporate finance services from Intermonte in the last 12 months (51 in total) is as follows:

BUY:	39.22 %
OUTPERFORM:	49.02 %
NEUTRAL:	11.76 %
UNDERPERFORM	00.00 %
SELL:	00.00 %

## CONFLICT OF INTEREST

## In order to disclose its possible conflicts of interest Intermonte SIM states that:

Intermonte SIM is acting as Global Coordinator in the proposed Unidata's capital increase with an agreement with the company for the publication of an equity research regarding the company and the transaction. Intermonte is also acting as Listing Agent in the proposed Unidata's Translisting. Intermonte will receive fees from the company for its activity as Global Coordinator and Listing Agent.

Listing Agent in the proposed Unidata's Translisting. Intermonte will receive fees from the company for its activity as Global Coordinator and Listing Agent. Within the last year, Intermonte SIM managed or co-managed/is managing or is co-managing an Institutional Offering and/or managed or co-managed/is managing or is co-managing or

Intermonte sing performes as a marker tracker for the rolowing companies: AZA, Anima, Audanta, Audanta

#### Emittente % Long/Short

#### © Copyright 2023 by Intermonte SIM - All rights reserved

It is a volation of national and international copyright laws to reproduce all or part of this publication by email, xerography, facsimile or any other means. The Copyright laws impose heavy liability for such infringement. The Reports of Intermonte SIM are provided to its clients only. If you are not a client of Intermonte SIM and receive emailed, faxed or copied versions of the reports from a source other than Intermonte SIM you are violating the Copyright Laws. This document is not for attribution in any publication, and you should not disseminate, distribute or copy this e-mail without the explicit written consent of Intermonte SIM.

INTERMONTE will take legal action against anybody transmitting/publishing its Research products without its express authorization. INTERMONTE Sim strongly believes its research product on Italian equities is a value added product and deserves to be adequately paid.

nonte Sim sales representatives can be contacted to discuss terms and conditions to be supplied the INTERMONTE research product.

INTERMONTE SIM is MIFID compliant - for our Best Execution Policy please check our Website MIFID